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Summary Forty-three patients with metastatic melanoma were treated with a 5 day (18 patients) and a 3 day
(25 patients) schedule of high-dose IL-2 11.7 MIU m2 and IFN-a 3 MIU m2 i.v. by bolus administration every
8 h, repeated every 21 days for a total of three courses. The 5 day schedule resulted in a high response rate of
41% (CI 18-67%), but was accompanied by severe cardiotoxicity (41%) and central nervous system toxicity
(28%). The 3 day schedule was associated with manageable toxicity, but yielded a moderate response rate of
20% (CI 7-43%).
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The biological agents, interferon alpha (IFN-a) and
interleukin 2 (IL-2) have shown evidence of activity against
metastatic melanoma. IFN-a produced objective tumor
regression in approximately 15% of patients (Creagan et
al., 1990; Kirkwood, 1991). IL-2, with or without lympho-
kine-activated killer cells, yielded response rates from 10-
25% (Rosenberg et al., 1989a; Parkinson et al., 1990;
Whitehead et al., 1991). With the combination of IL-2 and
IFN-a the reported response rates varied between 0-44%
(Rosenberg et al., 1989b; Dillman et al., 1993; Sparano et al.,
1993; Keilholz et al., 1993; Kruit et al., 1995). A phase I-II
study with increasing dose levels of bolus IL-2 and IFN-a
produced an objective response in 33% of patients
(Rosenberg et al., 1989b). The highest response rate of 44%
was reached with a schedule of IL-2 11.7 MIU m-2 and IFN-
a 3 MIU m-2 three times a day by intravenous bolus
administration, 5 days per cycle. We performed a phase II
study with this schedule in order to confirm these results.
Patients and methods
Patient population
The study was divided into two parts. Owing to the
occurrence of severe toxicity the 5-day regimen was replaced
by a 3-day schedule. All patients had histologically confirmed
metastatic melanoma. Eligibility criteria included: Karnofsky
performance status of at least 80, age between 18 and 70
years, no prior immunotherapy with IL-2 or IFN-a, no
metastases in the central nervous system, no cardiovascular
history, normal pulmonary function, serum creatinine < 1.25
times the upper limit of normal, or creatinine clearance
>50 ml ml-', leucocyte count >4.0 x 0 I -', platelet count
>100 x 109 1-, haemoglobin >9.5 g 100 ml-1 and normal
liver function with the exception of liver function distur-
bances owing to metastatic disease. All patients gave
informed consent and the study was carried out with ethical
committee approval.
Treatment
In part I of the study patients received recombinant IL-2 at a
dose of 11.7 MIU m-2 (Teceleukin; Hoffman La Roche,
Nutley, NJ, USA) and recombinant IFN-ai at a dose of 3
MIU m-2 (Roferon-A, Hoffman La Roche, Basle, Switzer-
land), each administered as an intravenous injection over
15 min, every 8 h on days 1-5. Treatment was repeated
every 21 days up to a total of three cycles. With this schedule
we were confronted with severe cardiotoxicity, albeit the first
3 days of treatment were relatively well tolerated. Therefore,
we decided to modify the treatment schedule, using the same
daily dosages of IL-2 and IFN-a, but now for 3 instead of 5
days.
The World Heath Organization (WHO) criteria were used
to grade toxicity (WHO, 1979). Treatment was permanently
discontinued if grade 3 neurotoxicity or cardiovascular
toxicity occurred. In case of grade 3 hypotension, therapy
was continued while giving symptomatic treatment with
colloids. If volume expansion gave no improvement
dopamine was added. Treatment was discontinued if the
patient remained hypotensive and/or oliguric. In all other
cases of grade 3 toxicity with the exception of fever, nausea/
vomiting and diarrhoea, immunotherapy was discontinued
until toxicity improved to grade 1 or resolved. Resumption of
treatment at 50% of the previous dose was allowed in the
next cycle if the grade 3 toxicity decreased to grade 1 or less.
Corticosteroid administration was not allowed, except in the
event of life-threatening toxicity.
The first tumour assessment was performed at 8 weeks
after the start of therapy. Response evaluations were repeated
every 4 weeks. Response categories were defined according to
WHO criteria (WHO, 1979). The treatment results were
analysed on an intent-to-treat basis. The median survival was
estimated using the Kaplan-Meier method.
Immunological monitoring
Absolute numbers of lymphocyte subsets and cytotoxic
activities of peripheral blood mononuclear cells (PBMCs)
were assessed in each treatment cycle, immediately before
the first administration and 1 week later. The lymphocyte
subsets defined by double-staining with CD3 and CD56,
CD4 and CD8, CD16 and CD19 monoclonal antibodies
were assessed by multicolour immunofluorescence and flow
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cytometry as described elsewhere (Gratama et al., 1996).
Cytotoxic activities of lymphocytes were determined in
standard 3 h 5'Cr-release assays. The K562 erythromyeloid
leukaemia cell line and the Daudi Burkitt's lymphoma cell
line were used as target cells for the assessment of natural
killer (NK) and lymphokine-activated killer (LAK) activities
respectively.
Results
Patient characteristics
Forty-three patients were entered in the study, 18 in part I
and 25 in part II. The characteristics of the eligible patients
are summarised in Table I. All eligible patients were
evaluable for response and toxicity. In the 5 day regimen,
one patient was ineligible because of unmeasurable disease.
Two patients had previously been treated with isolated limb
perfusion and one patient received radiotherapy before study
entry. In the 3 day regimen, two patients were pretreated with
adjuvant BCG or poly A-poly U.
Treatment characteristics
Of the 17 patients in part I, nine (53%) received three cycles,
three (18%) two cycles and five (29%) only one cycle. Eight
patients were taken off study early; six owing to grade 3-4
toxicity, one due to rapidly progressive disease and another
patient refused further treatment. The actual lymphokine
doses given during the first, second and third cycle, expressed
as a percentage of the planned dose, were 85%, 42% and
30% respectively.
Of the 25 patients in part II, 14 (56%), received three
cycles, five (20%) two cycles and six (24%) one cycle. The
lymphokine doses administered were 95%, 71% and 54% of
the planned dosages respectively. Treatment was discontinued
in one patient after only one single cytokine infusion owing
to grade 3 toxicity. He was considered a treatment failure.
Treatment results
Table II shows the results at response and survival. With the
5 day schedule the overall response rate was 41% (95%
Table I Patient characteristics
Part I
Evaluable patients
Age
Median
Range
Sex
Male
Female
Performance status (Karnofsky)
Median
Range
Prior therapy
Surgery
Immunotherapy
Chemotherapy
Radiotherapy
Distribution of metastatic sites
Lung
Lymph nodes
Subcutaneous
Liver
Other (adrenal, pancreas, bone)
Number of metastatic sites
1
2
3
4
5
17
48
29-61
9 (53%)
8 (47%)
90
80-100
17
2
1
9
7
6
6
8
6
4
4
2
1
25
41
20-69
16 (64%)
9 (36%)
90
80- 100
(100%)
(12%)
(6%)
(53%)
(41%)
(35%)
(35%)
(47%)
(35%)
(24%)
(24%)
(12%)
(6%)
25
2
0
0
10
17
12
9
9
7
7
7
4
(100%)
(8%)
(40%)
(68%)
(48%)
(36%)
(36%)
(28%)
(28%)
(28%)
(16%)
Table II Response to treatment
Part I Part II
Evaluable patients 17 25
Complete response (CR) 2 (12%) 0
Partial response (PR) 5 (29%) 5 (20%)
Overall response rate 41% 20%
Stable disease (SD) 3 (18%) 4 (26%)
Progressive disease (PD) 7 (41%) 16 (64%)
Median duration of response (months) 8.6 6.6
(range) (2.0-37.5) (3.9-9.9)
Median time to progression (months) 3.2 2.0
(range) (0.7-37.5) (0.5-9.9)
Median survival (months) 10.2 6.8
(range) (2.6-37.5) (0.9-24+)
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confidence interval 18-67%), including two complete
responses (CRs). The overall survival was 10.2 months
(range 2.6-37.5 months). With the 3 day schedule the
overall response rate was 20% (95% confidence interval 7-
43%). No CRs occurred. The overall survival was 6.8 months
(range 0.9-24+ months).
The adverse effects are shown in Table III. With the 5 day
schedule a high incidence of severe cardiac toxicity occurred.
Seven patients (41%) experienced cardiac adverse events;
cardiomyopathy in four, acute cardiac arrest, myocardial
Table III Adverse events
Part I Part II
Adverse event Grade 1/2 (%) Grade 3/4 (%) Grade 1/2 (%) Grade 3/4 (%)
Fever 12 88 52 48
Skin rash 76 0 64 0
Nausea/vomiting 76 18 40 52
Diarrhoea 53 35 48 44
Malaise 24 76 40 56
Weight gain 35 0 16 4
Hypotension 41 53 60 32
Cardiac 6 35 0 0
Dyspnoea 53 24 28 8
Neuropsychiatric 41 29 32 4
Oliguria 18 18 20 12
Creatinine 47 0 12 0
Alkaline phosphatase 76 6 56 4
Bilirubin 47 12 16 12
Transaminases 47 53 60 24
Anaemia 53 0 36 8
Thrombocytopenia 41 6 48 0
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Figure 1 Median absolute numbers ofCD56+, 3- (a), CD3 + (b), CD4+ (c) and CD8 + (d) lymphocytes in patients treated in the 5
day schedule (D) and in the 3 day schedule (U). Logarithmic scales have been used for the vertical axes in order to compress the
figure. Vertical bars represent confidence limits as defined by the 5th and 95th percentile of each group. The areas between the
horizontal lines represent the normal range of the different lymphocyte subsets as defined by the 5th and 95th percentiles of healthy
control persons.
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infarction and negative T-waves in one patient each. The
details of these patients have been reported elsewhere (Kruit
et al., 1994). No cardiotoxicity was observed in the 3 day
regimen.
Two-thirds of patients in the 5 day regimen suffered from
neuropsychiatric disturbances such as agitation, disorienta-
tion, confusion and overt psychosis. With the 3-day regimen
neuropsychiatric side-effects were encountered in about one-
third of patients and were mild in most cases. Neurotoxicity
completely resolved in all patients.
Immunological monitoring
Before therapy the absolute numbers of NK lymphocytes
(CD56+ 3- and CD16+), T lymphocytes (CD3+), helper/
inducer T lymphocytes (CD4+), cytotoxic/suppressor T
lymphocytes (CD8+) and B lymphocytes (CD19+) were
within the normal range. During therapy, the CD56+ 3-,
CD3+ and CD8+ lymphocyte counts gradually increased
above normal, whereas the CD4+ and CD19+ remained
within the normal range (Figure 1). The number of
lymphocytes after each treatment cycle (rebound lymphocy-
tosis) reached a higher value in the 5-day study (Figure 1,
open symbols) compared with the 3-day study (closed
symbols). NK and LAK cytotoxic activities of PBMCs
remained within the normal range in both parts of the
study, with a large variation between patients (data not
shown). There was no relationship between tumour response
and immune parameters.
Discussion
From an earlier performed dose-escalating study ofbolus IL-2
and IFN-a we selected the dosage schedule with the highest
response rate. This treatment schedule resulted in a 41%
response rate (95% CI 18-67%), which is identical to the
results reported by the NCI investigators (Rosenberg et al.,
1989b).
We observed a high incidence of severe cardiotoxicity.
Although myocardial toxicity was not so frequently
encountered in the NCI study as here, several cases of
myocardial infarction and elevation of cardiac enzyme levels
in 15% of treatment courses were reported (Rosenberg et al.,
1989b; Marincola et al., 1995). Also other recent literature
indicates that high-dose IL-2 regimens bear a high risk of
severe cardiotoxicity (Sznol et al., 1992; Atkins et al., 1993;
Fossa et al., 1993).
The second severe toxicity of the 5-day regimen consisted
of neuropsychiatric disturbances. Evidence from earlier
studies showed that the frequency and severity of these
side-effects are dose dependent (Denicoff et al., 1987; Dillman
et al., 1993; Sparano et al., 1993; Keilholz et al., 1993; Atkins
et al., 1993). The NCI investigators observed neurotoxicity
including coma in 54% of patients (Marincola et al., 1995).
Thus, the promising results on response were accompanied
by unacceptable toxicities. In an attempt to maintain the high
anti-tumour activity and to reduce the side-effects, we
shortened the treatment duration in the second part of the
study from 5 to 3 days. Indeed, the 3 day schedule was
accompanied by acceptable toxicity, however, the response
rate dropped to 20%. A direct comparison between the two
schedules is difficult, because it was not a randomised study
and the confidence intervals showed considerable overlap.
The response rate and survival duration ofthe 3 day schedule
were in the same range as observed in other studies of IL-2
and IFN-x in melanoma (Dillman et al., 1993; Sparano et al.,
1993; Kruit et al., 1995). In a recent progress report the NCI
investigators observed a similar decrease in treatment results
after modification of the treatment schedule (one instead of
three IFN-ax administrations per day), made necessary by the
encountered toxicity (Marincola et al., 1995). In general the
response rates and survival data ofcombined therapy of IL-2
and IFN-a in patients with metastatic melanoma appeared
not to be superior to treatment with IL-2 alone and IL-2 in
combination with lymphokine-activated killer cells (Bar et al.,
1990; Dutcher et al., 1991; Rosenberg et al., 1992, 1994;
Sparano et al., 1993; Marincola et al., 1995).
In summary, the combination of IL-2 and IFN-cx has not
meaningfully improved the clinical results that may be
obtained with IL-2 alone. Based on the possibly additive or
synergistic effects between cytotoxic agents and cytokines,
biochemotherapy may be an important new treatment
modality. Combinations of biological response modifiers
and cytostatics have produced encouraging response rates
(Richards et al., 1992; Khayat et al., 1993; Legha et al.,
1993).
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